7. Warrants

On January 4, 2016, the Company entered into an Asset Purchase Agreement with Novolytics Limited (the “Purchase Agreement”), to purchase certain preclinical materials and intangible assets, including patent rights, from Novolytics, an unrelated third party. In consideration for the assets acquired, the Company paid cash consideration of approximately $205,000 and issued warrants to purchase an aggregate of 170,000 shares of the Company’s common stock. The warrants have an exercise price of $12.00 per share and contain certain registration rights. The fair value of the warrants issued was $204,000, based on a Monte Carlo valuation model and are classified as equity within the consolidated balance sheets. The Company expensed the total value provided for the acquired assets of $409,000 as in-process research and development as of the acquisition date given there was no alternative future use of the acquired assets due to the early stage nature of the technology and pre-clinical materials.

On April 8, 2016, the Company modified 315,244 warrants held by the Holders, in accordance with the terms of the CSIA (see Note 6).

On June 3, 2016, the Company issued warrants exercisable for an aggregate of 1,063,830 shares of common stock at an exercise price of $2.25 per share in connection with the closing of a registered public offering of common stock and warrants (see Note 8).

The following table provides a summary of warrants outstanding, issued or exercised for the nine months ended September 30, 2016. Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of September 30, 2016.





			$2.25			$4.05 - $8.25				$10.75 - $23.00				Totals
				Weighted				Weighted				Weighted				Weighted
				Average				Average				Average				Average
				Exercise				Exercise				Exercise				Exercise
			Shares	Price		Shares		Price		Shares		Price		Shares		Price
Balance, December 31, 2015	-		-	$	-		694,062	$	5.82		515,587	$	11.39		1,209,649	$	8.19
Issuances			1,063,830		2.25		-		-		170,000		12.00		1,233,830		3.59
Exercises	-		-		-		-		-		-		-		-		-
Balance, September 30, 2016			1,063,830	$	2.25		694,062	$	5.82		685,587	$	11.54		2,443,479	$	5.87

Aggregate proceeds if exercised		$	2,393,618			$	4,036,474			$	7,914,572			$	14,344,664